The fixed combination efficacy assessment in patients with secondary neovascular glaucoma and diabetes mellitus

摘要

Purpose: To assess IOP-lowering efficacy of bimatoprost/timolol fixed combination (Ganfort ?) in patients with diabetes mellitus (DM) and uncontrolled secondary neovascular glaucoma (NG). Materials and Methods: Fifty patients (51 eyes) with uncontrolled secondary neovascular glaucoma and diabetes mellitus were enrolled in the study. All patients with an uncontrolled IOP have been proposed to switch current IOP-lowering therapy to Ganfort?. In case target IOP level was not reached filtration surgery was recommended. Ganfort? administration - once a day in the morning. Results: IOP-lowering has been observed in all patients when switched to Ganfort?. Mean IOP level was almost 3-x lower versus baseline in 72.5% of patients (37 eyes). The patients achieved target IOP of 15-17 mmHg. As a result, no surgical intervention was required. Significant IOP-lowering has been observed in another group of patients (14 eyes, 27.5 %) nevertheless due to glaucoma progression, these patients are still subjected to surgical treatment. Conclusion: IOP-lowering fixed combination Ganfort? (Allergan) can be used in patients with secondary neovascular glaucoma and diabetes mellitus as a drug of choice to control the IOP level. Even in cases when target IOP is not achieved, Ganfort? can be administered in pre-operative period and helps to reduce postoperative complications.